235 related articles for article (PubMed ID: 32970929)
41. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
42. FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer.
Zhu W; Huang M; Thakur A; Yan Y; Wu X
PeerJ; 2023; 11():e14827. PubMed ID: 36751636
[TBL] [Abstract][Full Text] [Related]
43. ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy.
Zhang H; Pang Y; Ma C; Li J; Wang H; Shao Z
Oncol Res; 2018 Apr; 26(3):421-429. PubMed ID: 28899456
[TBL] [Abstract][Full Text] [Related]
44. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.
Huang J; Liu K; Yu Y; Xie M; Kang R; Vernon P; Cao L; Tang D; Ni J
Autophagy; 2012 Feb; 8(2):275-7. PubMed ID: 22301993
[TBL] [Abstract][Full Text] [Related]
45. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
Cao X; Hou J; An Q; Assaraf YG; Wang X
Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
[TBL] [Abstract][Full Text] [Related]
46. Oncogenic functions of the transcription factor Nrf2.
Gañán-Gómez I; Wei Y; Yang H; Boyano-Adánez MC; García-Manero G
Free Radic Biol Med; 2013 Dec; 65():750-764. PubMed ID: 23820265
[TBL] [Abstract][Full Text] [Related]
47. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
48. Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Fan P; Zhang Y; Liu L; Zhao Z; Yin Y; Xiao X; Bauer N; Gladkich J; Mattern J; Gao C; Schemmer P; Gross W; Herr I
Cell Death Dis; 2016 Jun; 7(6):e2246. PubMed ID: 27253410
[TBL] [Abstract][Full Text] [Related]
49. [Role of high mobility group box-1 in chemo-sensitivity in cervical cancer].
Zhu F; Wu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 43(1):14-21. PubMed ID: 30154286
[TBL] [Abstract][Full Text] [Related]
50. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer.
Gąsiorkiewicz BM; Koczurkiewicz-Adamczyk P; Piska K; Pękala E
Invest New Drugs; 2021 Apr; 39(2):538-563. PubMed ID: 33159673
[TBL] [Abstract][Full Text] [Related]
51. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
[TBL] [Abstract][Full Text] [Related]
52. The functional roles of exosomal long non-coding RNAs in cancer.
Wang M; Zhou L; Yu F; Zhang Y; Li P; Wang K
Cell Mol Life Sci; 2019 Jun; 76(11):2059-2076. PubMed ID: 30683984
[TBL] [Abstract][Full Text] [Related]
53. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
[TBL] [Abstract][Full Text] [Related]
54. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.
Rostami N; Nikkhoo A; Ajjoolabady A; Azizi G; Hojjat-Farsangi M; Ghalamfarsa G; Yousefi B; Yousefi M; Jadidi-Niaragh F
Mol Diagn Ther; 2019 Aug; 23(4):467-487. PubMed ID: 31115798
[TBL] [Abstract][Full Text] [Related]
55. BCYRN1: An oncogenic lncRNA in diverse cancers.
Ghafouri-Fard S; Dashti S; Hussen BM; Farsi M; Taheri M
Pathol Res Pract; 2021 Apr; 220():153385. PubMed ID: 33647864
[TBL] [Abstract][Full Text] [Related]
56. Nanomaterials in crossroad of autophagy control in human cancers: Amplification of cell death mechanisms.
Zhao G; Wang Y; Fan Z; Xiong J; Ertas YN; Ashammakhi N; Wang J; Ma T
Cancer Lett; 2024 Jun; 591():216860. PubMed ID: 38583650
[TBL] [Abstract][Full Text] [Related]
57. ABHD5 interacts with BECN1 to regulate autophagy and tumorigenesis of colon cancer independent of PNPLA2.
Peng Y; Miao H; Wu S; Yang W; Zhang Y; Xie G; Xie X; Li J; Shi C; Ye L; Sun W; Wang L; Liang H; Ou J
Autophagy; 2016 Nov; 12(11):2167-2182. PubMed ID: 27559856
[TBL] [Abstract][Full Text] [Related]
58. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
59. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Xia J; He Y; Meng B; Chen S; Zhang J; Wu X; Zhu Y; Shen Y; Feng X; Guan Y; Kuang C; Guo J; Lei Q; Wu Y; An G; Li G; Qiu L; Zhan F; Zhou W
Mol Oncol; 2020 Apr; 14(4):763-778. PubMed ID: 31955515
[TBL] [Abstract][Full Text] [Related]
60. Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics.
Yang Y; Liu L; Tian Y; Gu M; Wang Y; Ashrafizadeh M; Reza Aref A; Cañadas I; Klionsky DJ; Goel A; Reiter RJ; Wang Y; Tambuwala M; Zou J
Cancer Lett; 2024 Apr; 587():216659. PubMed ID: 38367897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
